Eli Lilly-backed inflammatory disease drug developer has filed to raise up to $100m in an initial public offering in the United States.
China-based inflammatory disease drug developer Connect Biopharma Holdings has filed for a $100m initial public offering on the Nasdaq Global Market that would allow pharmaceutical firm Eli Lilly to exit. Connect Bio is developing therapeutics to treat T cell-driven inflammatory diseases, and its drug candidates include CBP-201, for inflammatory diseases like atopic dermatitis or asthma;…
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.